In summary, we have uncovered that SMARCA4/2 loss restricts IP3R3-mediated Ca2+ flux from the ER to mitochondria, leading to resistance to chemotherapy-induced apoptosis in ovarian and lung cancers. Here, SMARCA4 is linked to lung carcinoma.